Rhythm terminates RareStone license for IMCIVREE in China; reacquires rights for $6.3M

RHYTHM PHARMACEUTICALS, INC.

Termination of 2021 Exclusive License and Share Purchase agreements with RareStone Group Ltd.
Rhythm pays $6.3M repayment of upfront payment; returns all RareStone shares for no consideration.
Reacquires full rights to IMCIVREE (setmelanotide) in mainland China, Hong Kong, and Macau.
Global trial for hypothalamic obesity on track for Q2 2025 topline data readout.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.